Person:
TÜRK, HACI MEHMET

Profile Picture

Status

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

First Name

HACI MEHMET

Last Name

TÜRK

Name

Email Address

Birth Date

Filters

2010 - 2019272020 - 202447
Reset filters

Settings

Search Results

Now showing 1 - 10 of 74
  • No Thumbnail Available
    Publication
    An unusual presentation of extramedullary plasmacytoma in testis and review of the literature.
    (2010-12-01T00:00:00Z) Turk, HACI MEHMET; KOMURCU, S; OZET, A; KUZHAN, O; GÜNHAN, O; TÜRK, HACI MEHMET
  • Thumbnail Image
    Publication
    Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
    (2024-02-03) Wainberg Z. A.; Kang Y.; Lee K.; Qin S.; Yamaguchi K.; Kim I.; Saeed A.; Oh S. C.; Li J.; Turk H. M.; et al.; TÜRK, HACI MEHMET
    Background: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). Methods: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7.5 mg/kg) or placebo dose on cycle 1 day 8. All patients received mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months. Results: In the bemarituzumab-mFOLFOX6 (N = 77) and placebo-mFOLFOX6 (N = 78) arms, respectively, 59.7% and 66.7% of patients were FGFR2b-positive in ≥ 10% of tumor cells. The median PFS (95% confidence interval [CI]) was 9.5 months (7.3-13.7) with bemarituzumab-mFOLFOX6 and 7.4 months (5.7-8.4) with placebo-mFOLFOX6 (hazard ratio [HR], 0.72; 95% CI 0.49-1.08); median OS (95% CI) was 19.2 (13.6-24.2) and 13.5 (9.3-15.9) months, respectively (HR 0.77; 95% CI 0.52-1.14). Observed efficacy in FGFR2b-positive GC in ≥ 10% of tumor cells was: PFS: HR 0.43 (95% CI 0.26-0.73); OS: HR 0.52 (95% CI 0.31-0.85). No new safety findings were reported. Conclusions: In FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626).
  • No Thumbnail Available
    Publication
    Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
    (2021-08-01T00:00:00Z) Besiroglu, Mehmet; Demir, Tarik; Shbair, Abdallah T M; Yasin, Ayse Irem; Topcu, Atakan; Turk, HACI MEHMET; TÜRK, HACI MEHMET
  • Thumbnail Image
    Publication
    Incidental detection of prostate-specific antigen-negative metastatic prostate cancer initially presented with solitary pulmonary nodule on fluorodeoxyglucose positron emission tomography/computed tomography
    (2015-01-01) ERDOĞAN, EZGİ BAŞAK; Buyukpinarbasili, NUR; ZİYADE, SEDAT; AKMAN, Tolga; TÜRK, HACI MEHMET; AYDIN, MEHMET; ERDOĞAN, EZGİ BAŞAK; BÜYÜKPINARBAŞILI, NUR; ZİYADE, SEDAT; TÜRK, HACI MEHMET; AYDIN, MEHMET
    A 71-year-old male patient with solitary pulmonary nodule underwent fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) showing slightly increased FDG uptake in this nodule. In addition, PET/CT detected hypermetabolic sclerotic bone lesions in the right second rib and 7(th) thoracic vertebrae, which were interpreted as possible metastases, and mildly increased FDG uptake in the prostate gland highly suspicious of malignancy. The patient's prostate-specific antigen (PSA) level was within normal range (3.8 ng/dL). The histopathological examination of the lung nodule and right second rib lesion proved metastases from prostate cancer, then the prostate biopsy-confirmed prostate adenocarcinoma. The unique feature of this case is to emphasize the importance of performing PET/CT for solitary pulmonary nodule in detecting PSA-negative metastatic prostate cancer. This case indicated that it should be kept in mind that, even if the PSA is negative, a lung metastasis of prostate cancer may be an underlying cause in patients evaluated for solitary pulmonary nodule by FDG PET/CT.
  • No Thumbnail Available
    Publication
    Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma?
    (2020-08-06T00:00:00Z) Ersöz, Cevper; Demir, Tarık; Aliyev, Altay; Beşiroğlu, Mehmet; Araz, Murat; Köstek, Osman; Sakin, Abdullah; Shbair, Abdallah T M; Çoban, Ganime; Şeker, Mesut; Türk, HACI MEHMET; ERSÖZ, CEVPER; TÜRK, HACI MEHMET
  • No Thumbnail Available
    Publication
    Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
    (2022-10-13T00:00:00Z) Wainberg, Zev A; Enzinger, Peter C; Kang, Yoon-Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, HACI MEHMET; Teixeira, Alexandra; Borg, Christophe; Hitre, Erika; Udrea, Adrian A; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeño; Collins, Helen; Mitra, Siddhartha; Yang, Yingsi; Catenacci, Daniel V T; Lee, Keun-Wook; TÜRK, HACI MEHMET
    Magnetic monopoles are known to emerge as leading non-perturbative fluctuations in the lattice version of non-Abelian gauge theories in some gauges. In terms of the Dirac quantization condition, these monopoles have magnetic charge |Q_M|=2. Also, magnetic monopoles with |Q_M|=1 can be introduced on the lattice via the -t Hooft loop operator. We consider the |Q_M|=1,2 monopoles in the continuum limit of the lattice gauge theories. To substitute for the Dirac strings which cost no action on the lattice, we allow for singular gauge potentials which are absent in the standard continuum version. Once the Dirac strings are allowed, it turns possible to find a solution with zero action for a monopole--antimonopole pair. This implies equivalence of the standard and modified continuum versions in perturbation theory. To imitate the nonperturbative vacuum, we introduce then a nonsingular background. The modified continuum version of the gluodynamics allows in this case for monopoles with finite non-vanishing action. Using similar techniques, we construct the -t Hooft loop operator in the continuum and predict its behavior at small and large distances both at zero and high temperatures.
  • Thumbnail Image
    Publication
    Diagnostic performance of apparent diffusion coefficient values for the differentiation of intrahepatic cholangiocarcinoma from gastrointestinal adenocarcinoma liver metastases
    (2021-12-22T00:00:00Z) Yilmaz, TEMEL FATİH; Gultekin, Mehmet Ali; Turk, Hacı Mehmet; Cesme, Dilek Hacer; Besiroglu, Mehmet; Simsek, Melih; Toprak, Huseyin; Alkan, ALPAY; YILMAZ, TEMEL FATİH; TÜRK, HACI MEHMET; ÇEŞME, DİLEK HACER; ŞİMŞEK, MELİH; ALKAN, ALPAY; TOPRAK, HÜSEYİN
    Background: We aimed to investigate whether there is a difference between intrahepatic cholangiocarcinoma (IHCC) and liver metastases of gastrointestinal system (GIS) adenocarcinoma in terms of apparent diffusion coefficient (ADC) values. Patients and methods: From January 2018 to January 2020, we retrospectively examined 64 consecutive patients with liver metastases due to gastrointestinal system adenocarcinomas and 13 consecutive IHCC in our hospital's medical records. After exclusions, fifty-three patients with 53 liver metastases and 10 IHCC were included in our study. We divided the patients into two groups as IHCC and liver metastases of GIS adenocarcinoma. For mean apparent diffusion coefficient (ADCmean) values, the region of interests (ROI) was placed in solid portions of the lesions. ADCmean values of groups were compared. Results: The mean age of IHCC group was 62.50 ± 13.49 and mean age of metastases group was 61.15 ± 9.18. ADCmean values were significantly higher in the IHCC group compared to the metastatic group (p < 0.001). ROC curves method showed high diagnostic accuracy (AUC = 0.879) with cut-off value of < 1178 x 10-6 mm2/s for ADCmean (Sensitivity = 90.57, Specificity = 70.0, positive predictive value [PPV] = 94.1, negative predictive value [NPV] = 58.3) in differentiating adenocarcinoma metastases from IHCC. Conclusions: The present study results suggest that ADC values have a potential role for differentiation between IHCC and GIS adenocarcinoma liver metastases which may be valuable for patient management.
  • No Thumbnail Available
    Publication
  • Thumbnail Image
    Publication
    Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer.
    (2021-03-04T00:00:00Z) Bilgin, Sabriye Sennur; Gultekin, Mehmet Ali; Yurtsever, Ismail; Yilmaz, Temel Fatih; Cesme, Dilek Hacer; Bilgin, Melike; Topcu, Atakan; Besiroglu, Mehmet; Turk, Haci Mehmet; Alkan, ALPAY; Bilgin, Mehmet; GÜLTEKİN, MEHMET ALİ; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; ÇEŞME, DİLEK HACER; TÜRK, HACI MEHMET; ALKAN, ALPAY; BİLGİN, MEHMET
    Purpose: Histopathological differentiation of primary lung cancer is clinically important. We aimed to investigate whether diffusion tensor imaging (DTI) parameters of metastatic brain lesions could predict the histopathological types of the primary lung cancer. Methods: In total, 53 patients with 98 solid metastatic brain lesions of lung cancer were included. Lung tumors were subgrouped as non-small cell carcinoma (NSCLC) (n = 34) and small cell carcinoma (SCLC) (n = 19). Apparent diffusion coefficient (ADC) and Fractional anisotropy (FA) values were calculated from solid enhanced part of the brain metastases. The association between FA and ADC values and histopathological subtype of the primary tumor was investigated. Results: The mean ADC and FA values obtained from the solid part of the brain metastases of SCLC were significantly lower than the NSCLC metastases (P < 0.001 and P = 0.003, respectively). ROC curve analysis showed diagnostic performance for mean ADC values (AUC=0.889, P = < 0.001) and FA values (AUC = 0.677, P = 0.002). Cut-off value of > 0.909 × 10-3 mm2/s for mean ADC (Sensitivity = 80.3, Specificity = 83.8, PPV = 89.1, NPV = 72.1) and > 0.139 for FA values (Sensitivity = 80.3, Specificity = 54.1, PPV = 74.2, NPV= 62.5) revealed in differentiating NSCLC from NSCLC. Conclusion: DTI parameters of brain metastasis can discriminate SCLC and NSCLC. ADC and FA values of metastatic brain lesions due to the lung cancer may be an important tool to differentiate histopathological subgroups. DTI may guide clinicians for the management of intracranial metastatic lesions of lung cancer.
  • Thumbnail Image
    Publication
    Multiple myeloma mimicking metastatic lung cancer
    (2015-01-01) Furuncuoglu, Yavuz; Cirak, Yalcin; Turk, HACI MEHMET; BASAR, Melih; Ortapamuk, Hulya; KAUR, Ahmet Cemil; TÜRK, HACI MEHMET
    Multiple myeloma is a hematological malignancy characterized by a clonal proliferation of plasma cells in the bone marrow. Extramedullary dissemination of multiple myeloma is uncommon. Only in rare cases, the malignant plasma cells of multiple myeloma had infiltrated the lung parenchyma. In this case report, we presented a case of multiple myeloma with lung plasmacytoma, in a 42-year-old patient, hospitalized for pain and infiltrative mass in the right lung. The results of his initial evaluation with computed tomography and positron emission tomograpy scanning, resembled lung tumor with bone metastasis. Surprisingly, biopsies from lung tumor and bone metastasis, revealed malignant plasma cells. We found M spike in protein electrophoresis and lambda monoclonal band in immune electrophoresis. A bone marrow biopsy evaluation was done and justified multiple myeloma diagnosis before hematology referral. Multiple myeloma diagnosis at the age of 42 is quite rare.